Delaunay, Sylvain
Pascual, Gloria http://orcid.org/0000-0003-3810-6647
Feng, Bohai
Klann, Kevin http://orcid.org/0000-0003-2276-8128
Behm, Mikaela
Hotz-Wagenblatt, Agnes http://orcid.org/0000-0003-1523-2093
Richter, Karsten
Zaoui, Karim
Herpel, Esther
Münch, Christian http://orcid.org/0000-0003-3832-090X
Dietmann, Sabine
Hess, Jochen
Benitah, Salvador Aznar http://orcid.org/0000-0002-9059-5049
Frye, Michaela http://orcid.org/0000-0002-5636-6840
Article History
Received: 27 October 2020
Accepted: 24 May 2022
First Online: 29 June 2022
Competing interests
: S.A.B. is a co-founder and scientific advisor at ONA Therapeutics. J.H. receives commercial funding from CureVac AG and acts as a consultant and advisory board member for Bristol-Myers Squibb and MSD Sharp & Dohme. M.F. receives commercial funding from Merck. The other authors declare no competing interests.